Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center
Corresponding Author
Justin M. Watts
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Department of Medicine, Division of Hematology and Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA
Correspondence: Justin M. Watts, Clinical Research Building, 1120 NW 14th Street, Suite 610C, Miami, FL 33136, USA.
E-mail: [email protected]
Search for more papers by this authorAshwin Kishtagari
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Co-first author.Search for more papers by this authorMeier Hsu
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorMario E. Lacouture
Dermatology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorMichael A. Postow
Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorJae H. Park
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorEytan M. Stein
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorJulie Teruya-Feldstein
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorOmar Abdel-Wahab
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorSean M. Devlin
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorMartin S. Tallman
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorCorresponding Author
Justin M. Watts
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Department of Medicine, Division of Hematology and Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA
Correspondence: Justin M. Watts, Clinical Research Building, 1120 NW 14th Street, Suite 610C, Miami, FL 33136, USA.
E-mail: [email protected]
Search for more papers by this authorAshwin Kishtagari
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Co-first author.Search for more papers by this authorMeier Hsu
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorMario E. Lacouture
Dermatology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorMichael A. Postow
Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorJae H. Park
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorEytan M. Stein
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorJulie Teruya-Feldstein
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorOmar Abdel-Wahab
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorSean M. Devlin
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Search for more papers by this authorMartin S. Tallman
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Search for more papers by this authorSummary
Few studies have examined melanoma and non-melanoma skin cancer (NMSC) incidence rates after a diagnosis of hairy cell leukaemia (HCL). We assessed 267 HCL patients treated at Memorial Sloan Kettering Cancer Center (MSKCC) and Surveillance, Epidemiology and End Results (SEER) data for melanoma and NMSC incidence rates after HCL. Incidence data from MSKCC patients demonstrated a 10-year combined melanoma and NMSC skin cancer rate of 11·3%, melanoma 4·4% and NMSC 6·9%. Molecular analysis of skin cancers from MSKCC patients revealed activating RAS mutations in 3/9 patients, including one patient with melanoma. Of 4750 SEER patients with HCL, 55 (1·2%) had a subsequent diagnosis of melanoma. Standardized incidence ratios (SIRs) did not show that melanoma was more common in HCL patients versus the general population (SIR 1·3, 95% CI 0·78–2·03). Analysis of SEER HCL patients diagnosed before and after 1990 (approximately before and after purine analogue therapy was introduced) showed no evidence of an increased incidence after 1990. A better understanding of any potential association between HCL and skin cancer is highly relevant given ongoing trials using BRAF inhibitors, such as vemurafenib, for relapsed HCL, as RAS-mutant skin cancers could be paradoxically activated in these patients.
Supporting Information
| Filename | Description |
|---|---|
| bjh13528-sup-0001-FigS1.docxWord document, 26.8 KB | Fig S1.These are cumulative incidence curves estimating the risk of melanoma in both men and women (the dotted line represents males and the solid line females). We do not show any difference by gender group over time and the hazard ratio for risk of melanoma after HCL for males to females was not significant (HR 1.49, p=0.27). These data suggest that there was no difference in melanoma incidence by gender group over time. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- Agnew, K.L., Ruchlemer, R., Catovsky, D., Matutes, E. & Bunker, C.B. (2004) Cutaneous findings in chronic lymphocytic leukaemia. The British Journal of Dermatology, 150, 1129–1135.
- Au, W.Y., Klasa, R.J., Gallagher, R., Le, N., Gascoyne, R.D. & Connors, J.M. (1998) Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood, 92, 1160–1164.
- Bridges, N. & Steinberg, J.J. (1986) Aggressive squamous cell carcinoma of the skin after chronic lymphocytic leukemia. Journal of Surgical Oncology, 33, 27–30.
- Buschfort, C., Muller, M.R., Seeber, S., Rajewsky, M.F. & Thomale, J. (1997) DNA excision repair profiles of normal and leukemic human lymphocytes: functional analysis at the single-cell level. Cancer Research, 57, 651–658.
- Davidovitz, Y., Ballin, A. & Meytes, D. (1997) Flare-up of squamous cell carcinoma of the skin following fludarabine therapy for chronic lymphocytic leukemia. Acta Haematologica, 98, 44–46.
- Emile, J.-F., Diamond, E.L., Hélias-Rodzewicz, Z., Cohen-Aubart, F., Charlotte, F., Hyman, D.M., Kim, E., Rampal, R., Patel, M., Ganzel, C., Aumann, S., Faucher, G., Le Gall, C., Leroy, K., Colombat, M., Kahn, J.-E., Trad, S., Nizard, P., Donadieu, J., Taly, V., Amoura, Z., Abdel-Wahab, O. & Haroche, J. (2014) Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood, 124, 3016–3019.
- Hartley, B.E., Searle, A.E., Breach, N.M., Rhys-Evans, P.H. & Henk, J.M. (1996) Aggressive cutaneous squamous cell carcinoma of the head and neck in patients with chronic lymphocytic leukaemia. The Journal of Laryngology and Otology, 110, 694–695.
- Hisada, M., Chen, B.E., Jaffe, E.S. & Travis, L.B. (2007) Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. Journal of the National Cancer Institute, 99, 215–222.
- Kimball, A.B., Schenfeld, J., Accortt, N.A., Anthony, M.S., Rothman, K.J. & Pariser, D. (2014) Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. The British Journal of Dermatology, 170, 366–373.
- Lacouture, M.E., Duvic, M., Hauschild, A., Prieto, V.G., Robert, C., Schadendorf, D., Kim, C.C., McCormack, C.J., Myskowski, P.L., Spleiss, O., Trunzer, K., Su, F., Nelson, B., Nolop, K.B., Grippo, J.F., Lee, R.J., Klimek, M.J., Troy, J.L. & Joe, A.K. (2013) Analysis of dermatologic events in vemurafenib-treated patients with melanoma. The Oncologist, 18, 314–322.
- Larkin, J., Ascierto, P.A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., de la Merino, L.C., Dutriaux, C., Garbe, C., Sovak, M.A., Chang, I., Choong, N., Hack, S.P., McArthur, G.A. & Ribas, A. (2014) Combined vemurafenib and cobimetinib in BRAF -mutated melanoma. New England Journal of Medicine, 371, 1867–1876.
- Larsen, C.R., Hansen, P.B. & Clausen, N.T. (2002) Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues. American Journal of Hematology, 70, 48–50.
- Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.J., Chiarion Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B., Hansson, J., Utikal, J., Ferraresi, V., Kovalenko, N., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., DeMarini, D.J., Irani, J.G., Casey, M., Ouellet, D., Martin, A.M., Le, N., Patel, K. & Flaherty, K. (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. New England Journal of Medicine, 371, 1877–1888.
- Oberholzer, P.A., Kee, D., Dziunycz, P., Sucker, A., Kamsukom, N., Jones, R., Roden, C., Chalk, C.J., Ardlie, K., Palescandolo, E., Piris, A., MacConaill, L.E., Robert, C., Hofbauer, G.F.L., McArthur, G.A., Schadendorf, D. & Garraway, L.A. (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30, 316–321.
- Pierceall, W.E., Goldberg, L.H., Tainsky, M.A., Mukhopadhyay, T. & Ananthaswamy, H.N. (1991) Ras gene mutation and amplification in human nonmelanoma skin cancers. Molecular Carcinogenesis, 4, 196–202.
- Robak, T. (2004) Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. Hematology (Amsterdam, Netherlands), 9, 387–400.
- Robak, E. & Robak, T. (2007) Skin lesions in chronic lymphocytic leukemia. Leukemia & Lymphoma, 48, 855–865.
- Robak, T., Blonski, J.Z., Gora-Tybor, J., Kasznicki, M., Konopka, L., Ceglarek, B., Komarnicki, M., Lewandowski, K., Hellmann, A., Moskwa, A., Dmoszynska, A., Sokolowska, B., Dwilewicz-Trojaczek, A., Tomaszewska, A., Sulek, K. & Calbecka, M. (2004) Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. European Journal of Cancer (Oxford, England: 1990), 40, 383–389.
- Robert, C., Arnault, J.-P. & Mateus, C. (2011) RAF inhibition and induction of cutaneous squamous cell carcinoma. Current Opinion in Oncology, 23, 177–182.
- Rosenberg, J.D., Burian, C., Waalen, J. & Saven, A. (2014) Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood, 123, 177–183.
- Royle, J.A., Baade, P.D., Joske, D., Girschik, J. & Fritschi, L. (2011) Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. British Journal of Cancer, 105, 1076–1081.
- Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J.S., Kong, X., Koya, R.C., Flaherty, K.T., Chapman, P.B., Kim, M.J., Hayward, R., Martin, M., Yang, H., Wang, Q., Hilton, H., Hang, J.S., Noe, J., Lambros, M., et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. The New England Journal of Medicine, 366, 207–215.
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). (2014) SEER*Stat Database: Incidence – SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2013 Sub (2000-2011) <Katrina/Rita Population Adjustment> – Linked To County Attributes – Total U.S., 1969-2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014 (updated 5/7/2014), based on the November 2013 submission.
- Toner, G.C., Holmes, R., Kennedy, J.T. & Schwarz, M.A. (1987) Lethal skin cancers in hairy cell leukemia (two case reports). European Journal of Haematology, 39, 82–85.
- Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M.E., Busam, K., Carvajal, R.D., Egberts, F., Hauschild, A., Kashani-Sabet, M., Goldinger, S.M., Dummer, R., Long, G.V., McArthur, G., Scherag, A., Sucker, A. & Schadendorf, D. (2012) Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30, 2375–2383.
Citing Literature
